Cargando…
The promising novel therapies for familial hypercholesterolemia
BACKGROUND: The incidence of premature atherosclerotic cardiovascular disease in familial hypercholesterolemia (FH) is high. In recent years, novel therapeutic modalities have shown significant lipid‐lowering ability. In this paper, we summarize the recent developments in novel therapies for FH via...
Autores principales: | Chen, Ruoyu, Lin, Shaoyi, Chen, Xiaomin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279988/ https://www.ncbi.nlm.nih.gov/pubmed/35712827 http://dx.doi.org/10.1002/jcla.24552 |
Ejemplares similares
-
Two Novel Disease-Causing Mutations in the LDLR of Familial Hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021) -
The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021) -
In vitro assessment of the pathogenicity of the LDLR c.2160delC variant in familial hypercholesterolemia
por: Lin, Shaoyi, et al.
Publicado: (2023) -
The Polypill: From Promise to Pragmatism
por: Huffman, Mark D.
Publicado: (2015) -
The Rise of Consumer Health Wearables: Promises and Barriers
por: Piwek, Lukasz, et al.
Publicado: (2016)